Опухоли головы и шеи. 2016; 6: 67-72
ПРИМЕНЕНИЕ СОРАФЕНИБА (НЕКСАВАРА) В ЛЕЧЕНИИ БОЛЬНОЙ ДИССЕМИНИРОВАННЫМ РАКОМ ПАРАЩИТОВИДНЫХ ЖЕЛЕЗ (КЛИНИЧЕСКИЙ СЛУЧАЙ)
https://doi.org/10.17650/2222-1468-2016-6-4-67-72Аннотация
Рак паращитовидных желез является крайне редкой патологией, частота ее встречаемости составляет 0,005 % среди всех злокачественных заболеваний и менее чем 1 % среди пациентов с первичным гиперпаратиреозом. Диагностика может быть затруднена в связи со сходством клинической картины с аденомой паращитовидных желез и отсутствием четких морфологических признаков опухоли. Для диссеминированного рака паращитовидной железы нет стандартов лекарственной терапии вследствие редкой встречаемости данной патологии. Химиотерапия и лучевая терапия не показали значительной эффективности в лечении. Мы представляем клиническое наблюдение 27-летней больной диссеминированным раком паращитовидных желез с метастазами в легкие, которой ошибочно был установлен диагноз аденомы паращитовидной железы. После проведения иммуногистохимического исследования и установления диагноза больная успешно получает лечение мультикиназным ингибитором сорафенибом.
Список литературы
1. Schantz A., Castleman B. Parathyroid carcinoma. A study of 70 cases. Cancer 1973;31:600–5.
2. Handahl S.A., Fleming I.D., Fremgen A.M. et al. Two hundred eighty-six cases of parathyroid carcinoma treated in the U.S. between 1985–1995: a National Cancer Data Base Report. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer 1999;86:538–44.
3. Okamoto T. Parathyroid carcinoma: etiology, diagnosis, and treatment. World J Surg 2009;33(11):2343–54.
4. Рожинская Л.Я., Мокрышева Н.Г., Кузнецов Н.С. Алгоритмы обследования и лечения пациентов в эндокринологии. Методические рекомендации ФГУ «Эндокринологический научный центр». М., 2009. [Rozhinskaya L.Ya., Mokrysheva N.G., Kuznetsov N.S. Algorithms of examination and treatment of patients in endocrinology. Methodical recommendations of the FSI “Endocrinological research center”. Moscow, 2009. (In Russ.)].
5. Мокрышева Н.Г. Первичный гиперпаратиреоз: современное представление о проблеме. Лечение и профилактика 2013;2(6):143–52. [Mokrysheva N.G. Primary hyperparathyroidism: a modern view of the issue. Lechenie i profilaktika = Treatment and Prevention 2013;2(6):143–52. (In Russ.)].
6. Bilezikian J.P., Potts J.T., Fuleihan G.-H. et al. Summary Statement from a Workshop on Asymptomatic Primary Hyperparathyroidism: A Perspective for the 21st Century. J Bone Miner Res 2002;17 Suppl 2:N2–11.
7. Древаль А.В., Тевосян Л.Х. Первичный гиперпаратиреоз. Русский медицинский журнал 2015;(8):427. [Dreval’ A.V., Tevosyan L.Kh. Primary hyperparathyroidism. Russkiy meditsinskiy zhurnal = Russian Medical Journal 2015;(8):427. (In Russ.)].
8. Agarwal G., Dhingra S., Mishra S., Langenbecks K.N. Implantation of parathyroid carcinoma along fine needle aspiration track. Arch Surg 2006;391(6):623–6.
9. Spinelli C., Bonadio A., Berti P. et al. Cutaneous spreading of parathyroid carcinoma after fine needle aspiration cytology. J Endocrinol Inv 2000;23(4):255–7.
10. Brose M.S., Nutting C.M., Jarzab B. et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet 2014;384(9940):319–28. DOI: 10.1016/S0140-6736(14)60421-9.
11. Schlumberger M., Tahara M., Wirth L.J. et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med 2015;372(7):621–30. DOI: 10.1056/NEJMoa1406470.
Head and Neck Tumors (HNT). 2016; 6: 67-72
THE USE OF SORAFENIB (NEXAVAR) IN TREATMENT OF PATIENT WITH DISSEMINATED PARATHYROID CANCER: A CASE REPORT
https://doi.org/10.17650/2222-1468-2016-6-4-67-72Abstract
Parathyroid carcinoma (PC) is a rare neoplasm with a prevalence of only 0.005 % of all malignancies, and less than 1 % among patients with primary hyperparathyroidism. The diagnosis can be challenging due to the rarity of the disease, similarity of clinical features to parathyroid adenoma, and lack of reliable morphological signs of the tumor. For metastatic cancer of the parathyroid gland does not exist standard drug therapy due to the rare occurrence of this disease. Chemotherapy and radiotherapy failed to show any significant effect on the course of the disease. We report the case of a 27-year old woman with PC previously misdiagnosed as benign thyroid nodule and multiple lung metastases. After the immunohistochemical study and confirm of diagnosis PC the patient was treatment with multikinase inhibitor sorafenib successfully.
References
1. Schantz A., Castleman B. Parathyroid carcinoma. A study of 70 cases. Cancer 1973;31:600–5.
2. Handahl S.A., Fleming I.D., Fremgen A.M. et al. Two hundred eighty-six cases of parathyroid carcinoma treated in the U.S. between 1985–1995: a National Cancer Data Base Report. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer 1999;86:538–44.
3. Okamoto T. Parathyroid carcinoma: etiology, diagnosis, and treatment. World J Surg 2009;33(11):2343–54.
4. Rozhinskaya L.Ya., Mokrysheva N.G., Kuznetsov N.S. Algoritmy obsledovaniya i lecheniya patsientov v endokrinologii. Metodicheskie rekomendatsii FGU «Endokrinologicheskii nauchnyi tsentr». M., 2009. [Rozhinskaya L.Ya., Mokrysheva N.G., Kuznetsov N.S. Algorithms of examination and treatment of patients in endocrinology. Methodical recommendations of the FSI “Endocrinological research center”. Moscow, 2009. (In Russ.)].
5. Mokrysheva N.G. Pervichnyi giperparatireoz: sovremennoe predstavlenie o probleme. Lechenie i profilaktika 2013;2(6):143–52. [Mokrysheva N.G. Primary hyperparathyroidism: a modern view of the issue. Lechenie i profilaktika = Treatment and Prevention 2013;2(6):143–52. (In Russ.)].
6. Bilezikian J.P., Potts J.T., Fuleihan G.-H. et al. Summary Statement from a Workshop on Asymptomatic Primary Hyperparathyroidism: A Perspective for the 21st Century. J Bone Miner Res 2002;17 Suppl 2:N2–11.
7. Dreval' A.V., Tevosyan L.Kh. Pervichnyi giperparatireoz. Russkii meditsinskii zhurnal 2015;(8):427. [Dreval’ A.V., Tevosyan L.Kh. Primary hyperparathyroidism. Russkiy meditsinskiy zhurnal = Russian Medical Journal 2015;(8):427. (In Russ.)].
8. Agarwal G., Dhingra S., Mishra S., Langenbecks K.N. Implantation of parathyroid carcinoma along fine needle aspiration track. Arch Surg 2006;391(6):623–6.
9. Spinelli C., Bonadio A., Berti P. et al. Cutaneous spreading of parathyroid carcinoma after fine needle aspiration cytology. J Endocrinol Inv 2000;23(4):255–7.
10. Brose M.S., Nutting C.M., Jarzab B. et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet 2014;384(9940):319–28. DOI: 10.1016/S0140-6736(14)60421-9.
11. Schlumberger M., Tahara M., Wirth L.J. et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med 2015;372(7):621–30. DOI: 10.1056/NEJMoa1406470.
